Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock
Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized Controlled Trial of Adults Treated for Endotoxemia and Septic Shock
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1144
mi
from 43215
San Antonio, TX
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock
Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized Controlled Trial of Adults Treated for Endotoxemia and Septic Shock
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1144
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock
Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized Controlled Trial of Adults Treated for Endotoxemia and Septic Shock
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
341
mi
from 43215
Richmond, VA
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock
Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized Controlled Trial of Adults Treated for Endotoxemia and Septic Shock
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
341
mi
from 43215
Richmond, VA
Click here to add this to my saved trials
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock
Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized Controlled Trial of Adults Treated for Endotoxemia and Septic Shock
Status: Enrolling
Updated:  12/31/1969
1670
mi
from 43215
Calgary,
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock
Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized Controlled Trial of Adults Treated for Endotoxemia and Septic Shock
Status: Enrolling
Updated: 12/31/1969
1670
mi
from 43215
Calgary,
Click here to add this to my saved trials
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock
Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized Controlled Trial of Adults Treated for Endotoxemia and Septic Shock
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
394
mi
from 43215
Saint Louis, MO
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock
Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized Controlled Trial of Adults Treated for Endotoxemia and Septic Shock
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
394
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
CD34+Stem Cell Selection for Patients Receiving Partially Matched Family or Matched Unrelated Adult Donor Allogeneic Stem Cell Transplantations for Malignant and Non-Malignant Disease
Status: Enrolling
Updated:  12/31/1969
New York Medical College
491
mi
from 43215
Valhalla, NY
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
CD34+Stem Cell Selection for Patients Receiving Partially Matched Family or Matched Unrelated Adult Donor Allogeneic Stem Cell Transplantations for Malignant and Non-Malignant Disease
Status: Enrolling
Updated: 12/31/1969
New York Medical College
491
mi
from 43215
Valhalla, NY
Click here to add this to my saved trials
Miltefosine to Treat Mucocutaneous Leishmaniasis
Treatment of Mucocutaneous Leishmaniasis With Miltefosine
Status: Enrolling
Updated:  12/31/1969
for this treatment IND, each Physician will enter patients at his/her own facility. Below data is for Protocol central contact
320
mi
from 43215
Bethesda, MD
Miltefosine to Treat Mucocutaneous Leishmaniasis
Treatment of Mucocutaneous Leishmaniasis With Miltefosine
Status: Enrolling
Updated: 12/31/1969
for this treatment IND, each Physician will enter patients at his/her own facility. Below data is for Protocol central contact
320
mi
from 43215
Bethesda, MD
Click here to add this to my saved trials
Miltefosine to Treat Mucocutaneous Leishmaniasis
Treatment of Mucocutaneous Leishmaniasis With Miltefosine
Status: Enrolling
Updated:  12/31/1969
NIH
322
mi
from 43215
Bethesda, MD
Miltefosine to Treat Mucocutaneous Leishmaniasis
Treatment of Mucocutaneous Leishmaniasis With Miltefosine
Status: Enrolling
Updated: 12/31/1969
NIH
322
mi
from 43215
Bethesda, MD
Click here to add this to my saved trials
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer
The TOUCH Project: Reducing Distress and Promoting Quality of Life Via Caregiver Massage of Children Undergoing Treatment for Cancer
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences
312
mi
from 43215
Winston-Salem, NC
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer
The TOUCH Project: Reducing Distress and Promoting Quality of Life Via Caregiver Massage of Children Undergoing Treatment for Cancer
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences
312
mi
from 43215
Winston-Salem, NC
Click here to add this to my saved trials
Non-Invasive Assessment of Atherosclerosis in Patients With CGD and Other Disorders of the Immune System
Non-Invasive Assessment of Atherosclerosis in Patients With CGD and Other Disorders of the Immune System
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
Non-Invasive Assessment of Atherosclerosis in Patients With CGD and Other Disorders of the Immune System
Non-Invasive Assessment of Atherosclerosis in Patients With CGD and Other Disorders of the Immune System
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
Click here to add this to my saved trials
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas
Status: Enrolling
Updated:  12/31/1969
University of Chicago Comprehensive Cancer Center
274
mi
from 43215
Chicago, IL
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas
Status: Enrolling
Updated: 12/31/1969
University of Chicago Comprehensive Cancer Center
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas
Status: Enrolling
Updated:  12/31/1969
Decatur Memorial Hospital
314
mi
from 43215
Decatur, IL
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas
Status: Enrolling
Updated: 12/31/1969
Decatur Memorial Hospital
314
mi
from 43215
Decatur, IL
Click here to add this to my saved trials
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas
Status: Enrolling
Updated:  12/31/1969
Ingalls Memorial Hospital
267
mi
from 43215
Harvey, IL
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas
Status: Enrolling
Updated: 12/31/1969
Ingalls Memorial Hospital
267
mi
from 43215
Harvey, IL
Click here to add this to my saved trials
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas
Status: Enrolling
Updated:  12/31/1969
Illinois CancerCare-Peoria
349
mi
from 43215
Peoria, IL
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas
Status: Enrolling
Updated: 12/31/1969
Illinois CancerCare-Peoria
349
mi
from 43215
Peoria, IL
Click here to add this to my saved trials
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas
Status: Enrolling
Updated:  12/31/1969
Central Illinois Hematology Oncology Center
351
mi
from 43215
Springfield, IL
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas
Status: Enrolling
Updated: 12/31/1969
Central Illinois Hematology Oncology Center
351
mi
from 43215
Springfield, IL
Click here to add this to my saved trials
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas
Status: Enrolling
Updated:  12/31/1969
Fort Wayne Medical Oncology and Hematology Inc-Parkview
139
mi
from 43215
Fort Wayne, IN
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas
Status: Enrolling
Updated: 12/31/1969
Fort Wayne Medical Oncology and Hematology Inc-Parkview
139
mi
from 43215
Fort Wayne, IN
Click here to add this to my saved trials
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas
Status: Enrolling
Updated:  12/31/1969
Indiana University Melvin and Bren Simon Cancer Center
166
mi
from 43215
Indianapolis, IN
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas
Status: Enrolling
Updated: 12/31/1969
Indiana University Melvin and Bren Simon Cancer Center
166
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas
Status: Enrolling
Updated:  12/31/1969
University of Maryland Greenebaum Cancer Center
343
mi
from 43215
Baltimore, MD
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas
Status: Enrolling
Updated: 12/31/1969
University of Maryland Greenebaum Cancer Center
343
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas
Status: Enrolling
Updated:  12/31/1969
Northwestern University
274
mi
from 43215
Chicago, IL
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas
Status: Enrolling
Updated: 12/31/1969
Northwestern University
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas
Status: Enrolling
Updated:  12/31/1969
Southern Illinois University School of Medicine
351
mi
from 43215
Springfield, IL
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas
Status: Enrolling
Updated: 12/31/1969
Southern Illinois University School of Medicine
351
mi
from 43215
Springfield, IL
Click here to add this to my saved trials
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas
Status: Enrolling
Updated:  12/31/1969
Mercy Hospital Saint Louis
406
mi
from 43215
Saint Louis, MO
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas
Status: Enrolling
Updated: 12/31/1969
Mercy Hospital Saint Louis
406
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated:  12/31/1969
Providence Hospital Clinical Research Center
328
mi
from 43215
Washington,
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated: 12/31/1969
Providence Hospital Clinical Research Center
328
mi
from 43215
Washington,
Click here to add this to my saved trials
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated:  12/31/1969
Atlanta Institute for Medical Research, Inc
433
mi
from 43215
Decatur, GA
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated: 12/31/1969
Atlanta Institute for Medical Research, Inc
433
mi
from 43215
Decatur, GA
Click here to add this to my saved trials
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated:  12/31/1969
Wellstar Infectious Disease
423
mi
from 43215
Marietta, GA
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated: 12/31/1969
Wellstar Infectious Disease
423
mi
from 43215
Marietta, GA
Click here to add this to my saved trials
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated:  12/31/1969
Gastrointestinal Specialists of Georgia
425
mi
from 43215
Marietta, GA
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated: 12/31/1969
Gastrointestinal Specialists of Georgia
425
mi
from 43215
Marietta, GA
Click here to add this to my saved trials
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated:  12/31/1969
University of Chicago
270
mi
from 43215
Chicago, IL
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated: 12/31/1969
University of Chicago
270
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated:  12/31/1969
University of Kansas Medical Center
627
mi
from 43215
Kansas City, KA
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated: 12/31/1969
University of Kansas Medical Center
627
mi
from 43215
Kansas City, KA
Click here to add this to my saved trials
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated:  12/31/1969
DiGiovanna Institute for Medical Education and Research
505
mi
from 43215
North Massapequa, NY
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated: 12/31/1969
DiGiovanna Institute for Medical Education and Research
505
mi
from 43215
North Massapequa, NY
Click here to add this to my saved trials
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated:  12/31/1969
MeritCare Clinical Research
837
mi
from 43215
Fargo, ND
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated: 12/31/1969
MeritCare Clinical Research
837
mi
from 43215
Fargo, ND
Click here to add this to my saved trials
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated:  12/31/1969
Remington Davis Inc.
1
mi
from 43215
Columbus, OH
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated: 12/31/1969
Remington Davis Inc.
1
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated:  12/31/1969
MedStar Washington Hospital Center
328
mi
from 43215
Washington,
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated: 12/31/1969
MedStar Washington Hospital Center
328
mi
from 43215
Washington,
Click here to add this to my saved trials
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated:  12/31/1969
Idaho Falls Infectious Disease, PLLC
1691
mi
from 43215
Idaho, ID
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated: 12/31/1969
Idaho Falls Infectious Disease, PLLC
1691
mi
from 43215
Idaho, ID
Click here to add this to my saved trials
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated:  12/31/1969
Ochsner Clinic Foundation
800
mi
from 43215
New Orleans, LA
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated: 12/31/1969
Ochsner Clinic Foundation
800
mi
from 43215
New Orleans, LA
Click here to add this to my saved trials
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated:  12/31/1969
Metropolitan Gastroentrology Group
324
mi
from 43215
Chevy Chase, MD
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated: 12/31/1969
Metropolitan Gastroentrology Group
324
mi
from 43215
Chevy Chase, MD
Click here to add this to my saved trials
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated:  12/31/1969
Tufts University School of Medicine
643
mi
from 43215
Boston, MA
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated: 12/31/1969
Tufts University School of Medicine
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated:  12/31/1969
Henry Ford Health System
165
mi
from 43215
Detroit, MI
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated: 12/31/1969
Henry Ford Health System
165
mi
from 43215
Detroit, MI
Click here to add this to my saved trials
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated:  12/31/1969
183
mi
from 43215
Keego Harbor, MI
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated: 12/31/1969
183
mi
from 43215
Keego Harbor, MI
Click here to add this to my saved trials
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated:  12/31/1969
William Beaumont Hospital
176
mi
from 43215
Royal Oak, MI
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated: 12/31/1969
William Beaumont Hospital
176
mi
from 43215
Royal Oak, MI
Click here to add this to my saved trials
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated:  12/31/1969
Univ of Minnesota
624
mi
from 43215
Minneapolis, MN
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated: 12/31/1969
Univ of Minnesota
624
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated:  12/31/1969
Mercury Street Medical Group - Research Group
1538
mi
from 43215
Butte, MT
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated: 12/31/1969
Mercury Street Medical Group - Research Group
1538
mi
from 43215
Butte, MT
Click here to add this to my saved trials
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences
312
mi
from 43215
Winston-Salem, NC
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences
312
mi
from 43215
Winston-Salem, NC
Click here to add this to my saved trials
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated:  12/31/1969
University of Calgary, Foothills Medical Center
1670
mi
from 43215
Calgary,
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated: 12/31/1969
University of Calgary, Foothills Medical Center
1670
mi
from 43215
Calgary,
Click here to add this to my saved trials
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated:  12/31/1969
Central Florida Internists
816
mi
from 43215
Saint Cloud, FL
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated: 12/31/1969
Central Florida Internists
816
mi
from 43215
Saint Cloud, FL
Click here to add this to my saved trials
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated:  12/31/1969
Missouri Baptist Medical Center
407
mi
from 43215
Saint Louis, MO
Study of CB-183,315 in Participants With Clostridium Difficile Infection
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.
Status: Enrolling
Updated: 12/31/1969
Missouri Baptist Medical Center
407
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
HIV and Fat Accumulation
Metabolic Abnormalities, Telmisartan and HIV Infection
Status: Enrolling
Updated:  12/31/1969
UCLA CARE Ctr
1973
mi
from 43215
Los Angeles, CA
HIV and Fat Accumulation
Metabolic Abnormalities, Telmisartan and HIV Infection
Status: Enrolling
Updated: 12/31/1969
UCLA CARE Ctr
1973
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Gardasil Vaccination in Post Stem Cell Transplant Patients
A Phase I Trial of Safety and Immunogenicity of Gardasil Vaccination Post Stem Cell Transplantation in Patients With and Without Immunosuppression
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
Gardasil Vaccination in Post Stem Cell Transplant Patients
A Phase I Trial of Safety and Immunogenicity of Gardasil Vaccination Post Stem Cell Transplantation in Patients With and Without Immunosuppression
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
Click here to add this to my saved trials
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies
Status: Enrolling
Updated:  12/31/1969
University Hospitals Seidman Cancer Center
129
mi
from 43215
Cleveland, OH
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies
Status: Enrolling
Updated: 12/31/1969
University Hospitals Seidman Cancer Center
129
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment
A Prospective, Multicenter, Randomized, Evaluator-blinded, Comparator-controlled Study to Describe the Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin Structure Infections (cSSSI) and Staphylococcus Aureus Bacteremia Among Subjects With Moderate or Severe Renal Impairment
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
328
mi
from 43215
Washington,
Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment
A Prospective, Multicenter, Randomized, Evaluator-blinded, Comparator-controlled Study to Describe the Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin Structure Infections (cSSSI) and Staphylococcus Aureus Bacteremia Among Subjects With Moderate or Severe Renal Impairment
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
328
mi
from 43215
Washington,
Click here to add this to my saved trials
Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment
A Prospective, Multicenter, Randomized, Evaluator-blinded, Comparator-controlled Study to Describe the Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin Structure Infections (cSSSI) and Staphylococcus Aureus Bacteremia Among Subjects With Moderate or Severe Renal Impairment
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
430
mi
from 43215
Decatur, GA
Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment
A Prospective, Multicenter, Randomized, Evaluator-blinded, Comparator-controlled Study to Describe the Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin Structure Infections (cSSSI) and Staphylococcus Aureus Bacteremia Among Subjects With Moderate or Severe Renal Impairment
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
430
mi
from 43215
Decatur, GA
Click here to add this to my saved trials
Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment
A Prospective, Multicenter, Randomized, Evaluator-blinded, Comparator-controlled Study to Describe the Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin Structure Infections (cSSSI) and Staphylococcus Aureus Bacteremia Among Subjects With Moderate or Severe Renal Impairment
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1952
mi
from 43215
Azusa, CA
Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment
A Prospective, Multicenter, Randomized, Evaluator-blinded, Comparator-controlled Study to Describe the Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin Structure Infections (cSSSI) and Staphylococcus Aureus Bacteremia Among Subjects With Moderate or Severe Renal Impairment
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1952
mi
from 43215
Azusa, CA
Click here to add this to my saved trials
Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment
A Prospective, Multicenter, Randomized, Evaluator-blinded, Comparator-controlled Study to Describe the Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin Structure Infections (cSSSI) and Staphylococcus Aureus Bacteremia Among Subjects With Moderate or Severe Renal Impairment
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1972
mi
from 43215
Los Angeles, CA
Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment
A Prospective, Multicenter, Randomized, Evaluator-blinded, Comparator-controlled Study to Describe the Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin Structure Infections (cSSSI) and Staphylococcus Aureus Bacteremia Among Subjects With Moderate or Severe Renal Impairment
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1972
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials